International Assets Investment Management LLC Increases Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

International Assets Investment Management LLC lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 248,773.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 104,527 shares of the company’s stock after acquiring an additional 104,485 shares during the period. International Assets Investment Management LLC’s holdings in Medpace were worth $32,041,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of MEDP. Rice Hall James & Associates LLC lifted its holdings in shares of Medpace by 12.1% during the first quarter. Rice Hall James & Associates LLC now owns 183,556 shares of the company’s stock worth $30,028,000 after purchasing an additional 19,884 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Medpace by 28.3% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,581 shares of the company’s stock worth $259,000 after purchasing an additional 349 shares during the period. Cetera Advisor Networks LLC lifted its holdings in shares of Medpace by 26.1% during the first quarter. Cetera Advisor Networks LLC now owns 2,304 shares of the company’s stock worth $377,000 after purchasing an additional 477 shares during the period. Rhumbline Advisers lifted its holdings in shares of Medpace by 2.4% during the first quarter. Rhumbline Advisers now owns 78,755 shares of the company’s stock worth $12,884,000 after purchasing an additional 1,827 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Medpace by 10.5% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,537 shares of the company’s stock worth $1,724,000 after purchasing an additional 1,005 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a report on Saturday, March 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price for the company. Robert W. Baird raised their target price on Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a report on Wednesday, February 14th. Finally, UBS Group raised Medpace from a “neutral” rating to a “buy” rating and raised their target price for the company from $282.00 to $452.00 in a report on Thursday, February 15th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, Medpace has an average rating of “Moderate Buy” and a consensus target price of $382.00.

Insider Transactions at Medpace

In other news, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the transaction, the vice president now owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Ashley M. Keating sold 250 shares of Medpace stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $409.87, for a total transaction of $102,467.50. Following the completion of the sale, the director now owns 250 shares in the company, valued at approximately $102,467.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The disclosure for this sale can be found here. Insiders sold 189,340 shares of company stock valued at $76,651,647 in the last 90 days. 25.70% of the stock is currently owned by insiders.

Medpace Stock Performance

Medpace stock opened at $404.77 on Wednesday. Medpace Holdings, Inc. has a one year low of $185.43 and a one year high of $419.42. The business has a fifty day moving average of $382.54 and a two-hundred day moving average of $312.99. The company has a market cap of $12.54 billion, a P/E ratio of 45.58, a price-to-earnings-growth ratio of 2.12 and a beta of 1.38.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 12th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.24. The business had revenue of $498.40 million during the quarter, compared to the consensus estimate of $498.72 million. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The business’s revenue was up 26.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.12 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 10.53 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.